Glucagon Like Peptide-1 (GLP-1) Agonists Market Report

Global and Region Glucagon Like Peptide-1 (GLP-1) Agonists Market Demand & Opportunity Outlook 2022-2028

  • POSTDATE：Aug 03, 2022
  • PAGES：154
  • REPORT CODE：GMM1012467
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.

    Eli Lilly, Sanofi, GSK, Bristol-Myers Squibb, AstraZeneca are the leader of the industry, and hold the key technologies and patents, with high-end customers. They have formed global market channel of the industry. However, with the future expanding market, there will be more manufacturers in the future.

    The report details the trend, potential and market size of Glucagon Like Peptide-1 (GLP-1) Agonists market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.

    The first part (Chapter1-7) mainly covers the qualitative analysis of Glucagon Like Peptide-1 (GLP-1) Agonistsmarket, defines the market attractiveness level of Glucagon Like Peptide-1 (GLP-1) Agonists market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.

    The second part (Chapter8-12), based on the segmentation of Glucagon Like Peptide-1 (GLP-1) Agonists industry, describes the types of Glucagon Like Peptide-1 (GLP-1) Agonists market, the applications of major players and the market size, and deeply analyzes the current situation of the global Glucagon Like Peptide-1 (GLP-1) Agonists market and the development prospects and opportunities of Glucagon Like Peptide-1 (GLP-1) Agonists industry.

    The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.

    As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Glucagon Like Peptide-1 (GLP-1) Agonists market in Chapter 13.

    By Player:

    • Eli Lilly

    • Sanofi

    • GSK

    • Bristol-Myers Squibb

    • AstraZeneca

    • Novo Nordisk

    • Amylin

    By Type:

    • Exenatied

    • Liraglutide

    • Lixisenatide

    • Albiglutide

    • Dulaglutide

    By End-User:

    • Hospital

    • Pharmacy

    • Other

    By Geography:

    • United States

    • Europe

    • China

    • Japan

    • India

    • South Korea

  • TABLE OF CONTENT

    1 Introduction

    • 1.1 Market Definition

    • 1.2 Market Segment Analysis

    • 1.3 Market Size 2022

    • 1.4 Glucagon Like Peptide-1 (GLP-1) Agonists Market Outlook: Forecast for 2022 - 2028

    • 1.5 Pricing Analysis

    2 Executive Summary

    3 Glucagon Like Peptide-1 (GLP-1) Agonists Market Lineage Outlook

    • 3.1 Parent Market Outlook

    • 3.2 Related/Ancillary Market Outlook

    • 3.3 Penetration & Growth Prospect Mapping, 2022

    4 Market Analysis Tools: Porter's Five Forces

    • 4.1 Supplier Power

    • 4.2 Buyer Power

    • 4.3 Substitution Threat

    • 4.4 Threat of New Entrants

    • 4.5 Competitive Rivalry

    5 Glucagon Like Peptide-1 (GLP-1) Agonists Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)

    • 5.1 Political/Legal Landscape

    • 5.2 Economic Landscape

    • 5.3 Social Landscape

    • 5.4 Technology Landscape

    6 Glucagon Like Peptide-1 (GLP-1) Agonists Market - Value Chain Analysis

    • 6.1 Industry's Value Chain Analysis

    • 6.2 Product Life Cycle

    • 6.3 User Perspective Analysis

    7 Region and Country-wise Glucagon Like Peptide-1 (GLP-1) Agonists Market Analysis and Outlook to 2022

    • 7.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Consumption (2017-2022)

    • 7.2 United States Glucagon Like Peptide-1 (GLP-1) Agonists Consumption (2017-2022)

    • 7.3 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Consumption (2017-2022)

    • 7.4 China Glucagon Like Peptide-1 (GLP-1) Agonists Consumption (2017-2022)

    • 7.5 Japan Glucagon Like Peptide-1 (GLP-1) Agonists Consumption (2017-2022)

    • 7.6 India Glucagon Like Peptide-1 (GLP-1) Agonists Consumption (2017-2022)

    • 7.7 South Korea Glucagon Like Peptide-1 (GLP-1) Agonists Consumption (2017-2022)

    8 Region and Country-wise Glucagon Like Peptide-1 (GLP-1) Agonists Market Analysis and Outlook to 2028

    • 8.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast (2022-2028)

    • 8.2 United States Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast (2022-2028)

    • 8.3 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast (2022-2028)

    • 8.4 China Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast (2022-2028)

    • 8.5 Japan Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast (2022-2028)

    • 8.6 India Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast (2022-2028)

    • 8.7 South Korea Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast (2022-2028)

    9 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Outlook by Types and Applications to 2022

    • 9.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Exenatied Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Liraglutide Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Lixisenatide Consumption and Growth Rate (2017-2022)

      • 9.1.4 Global Albiglutide Consumption and Growth Rate (2017-2022)

      • 9.1.5 Global Dulaglutide Consumption and Growth Rate (2017-2022)

    • 9.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Hospital Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Pharmacy Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Other Consumption and Growth Rate (2017-2022)

    10 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Outlook by Types and Applications to 2028

    • 10.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast and Growth Rate by Type (2022-2028)

      • 10.1.1 Global Exenatied Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.2 Global Liraglutide Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.3 Global Lixisenatide Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.4 Global Albiglutide Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.5 Global Dulaglutide Consumption Forecast and Growth Rate (2022-2028)

    • 10.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast and Growth Rate by Application (2022-2028)

      • 10.2.1 Global Hospital Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.2 Global Pharmacy Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.3 Global Other Consumption Forecast and Growth Rate (2022-2028)

    11 Global Glucagon Like Peptide-1 (GLP-1) Agonists Import and Export Analysis (Top 5 Countries)

    • 11.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Import by Region (Top 5 Countries) (2017-2028)

    • 11.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Export by Region (Top 5 Countries) (2017-2028)

    12 Coronavirus Disease (COVID-19) Impact

    • 12.1 Industry Impact Analysis

    • 12.2 Glucagon Like Peptide-1 (GLP-1) Agonists Market Outlook to 2028 - COVID-19 Affected Forecasts

    13 Competition Matrix

    • 13.1 Target Markets

    • 13.2 Comprehensive Analysis of Products in Competitive Markets

    14 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Competitive Analysis

    • 14.1 Eli Lilly

      • 14.1.1 Eli Lilly Company Details

      • 14.1.2 Eli Lilly Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Price, Value and Gross Profit (2017-2022)

      • 14.1.3 Eli Lilly Glucagon Like Peptide-1 (GLP-1) Agonists Product and Service

    • 14.2 Sanofi

      • 14.2.1 Sanofi Company Details

      • 14.2.2 Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Price, Value and Gross Profit (2017-2022)

      • 14.2.3 Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Product and Service

    • 14.3 GSK

      • 14.3.1 GSK Company Details

      • 14.3.2 GSK Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Price, Value and Gross Profit (2017-2022)

      • 14.3.3 GSK Glucagon Like Peptide-1 (GLP-1) Agonists Product and Service

    • 14.4 Bristol-Myers Squibb

      • 14.4.1 Bristol-Myers Squibb Company Details

      • 14.4.2 Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Price, Value and Gross Profit (2017-2022)

      • 14.4.3 Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Product and Service

    • 14.5 AstraZeneca

      • 14.5.1 AstraZeneca Company Details

      • 14.5.2 AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Price, Value and Gross Profit (2017-2022)

      • 14.5.3 AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Product and Service

    • 14.6 Novo Nordisk

      • 14.6.1 Novo Nordisk Company Details

      • 14.6.2 Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Price, Value and Gross Profit (2017-2022)

      • 14.6.3 Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Product and Service

    • 14.7 Amylin

      • 14.7.1 Amylin Company Details

      • 14.7.2 Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Price, Value and Gross Profit (2017-2022)

      • 14.7.3 Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Product and Service

    15 Appendix


    TABLE OF CHARTS

    • Table Definition of Glucagon Like Peptide-1 (GLP-1) Agonists

    • Figure Glucagon Like Peptide-1 (GLP-1) Agonists Picture

    • Table Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Glucagon Like Peptide-1 (GLP-1) Agonists Market: Year-over-year Growth 2022 - 2028 (%)

    • Table Parent Market Analysis

    • Figure Parent Market Price

    • Table Related/Ancillary Market Outlook Analysis

    • Table Supplier Power Analysis

    • Table Buyer Power Analysis

    • Table Substitution Threat Analysis

    • Table Threat of New Entrants Analysis

    • Table Competitive Rivalry Analysis

    • Figure Global Glucagon Like Peptide-1 (GLP-1) Agonists Consumption by Country (2017-2022)

    • Figure United States Glucagon Like Peptide-1 (GLP-1) Agonists Consumption and Growth Rate (2017-2022)

    • Table Europe Glucagon Like Peptide-1 (GLP-1) Agonists Consumption and Growth Rate (2017-2022)

    • Figure China Glucagon Like Peptide-1 (GLP-1) Agonists Consumption and Growth Rate (2017-2022)

    • Figure Japan Glucagon Like Peptide-1 (GLP-1) Agonists Consumption and Growth Rate (2017-2022)

    • Figure India Glucagon Like Peptide-1 (GLP-1) Agonists Consumption and Growth Rate (2017-2022)

    • Figure South Korea Glucagon Like Peptide-1 (GLP-1) Agonists Consumption and Growth Rate (2017-2022)

    • Figure Global Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast by Country (2022-2028)

    • Figure United States Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast and Growth Rate (2022-2028)

    • Figure China Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Exenatied Consumption and Growth Rate (2017-2022)

    • Figure Global Liraglutide Consumption and Growth Rate (2017-2022)

    • Figure Global Lixisenatide Consumption and Growth Rate (2017-2022)

    • Figure Global Albiglutide Consumption and Growth Rate (2017-2022)

    • Figure Global Dulaglutide Consumption and Growth Rate (2017-2022)

    • Figure Global Hospital Consumption and Growth Rate (2017-2022)

    • Figure Global Pharmacy Consumption and Growth Rate (2017-2022)

    • Figure Global Other Consumption and Growth Rate (2017-2022)

    • Figure Global Exenatied Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Liraglutide Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Lixisenatide Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Albiglutide Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Dulaglutide Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hospital Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Pharmacy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Other Consumption Forecast and Growth Rate (2022-2028)

    • Table Global Glucagon Like Peptide-1 (GLP-1) Agonists Import by Region (Top 5 Countries) (2017-2028)

    • Table Global Glucagon Like Peptide-1 (GLP-1) Agonists Export by Region (Top 5 Countries) (2017-2028)

    • Table Eli Lilly (Foundation Year, Company Profile and etc.)

    • Table Eli Lilly Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Price, Value and Gross Profit (2017-2022)

    • Table Eli Lilly Glucagon Like Peptide-1 (GLP-1) Agonists Product and Service

    • Table Sanofi (Foundation Year, Company Profile and etc.)

    • Table Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Price, Value and Gross Profit (2017-2022)

    • Table Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Product and Service

    • Table GSK (Foundation Year, Company Profile and etc.)

    • Table GSK Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Price, Value and Gross Profit (2017-2022)

    • Table GSK Glucagon Like Peptide-1 (GLP-1) Agonists Product and Service

    • Table Bristol-Myers Squibb (Foundation Year, Company Profile and etc.)

    • Table Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Price, Value and Gross Profit (2017-2022)

    • Table Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Product and Service

    • Table AstraZeneca (Foundation Year, Company Profile and etc.)

    • Table AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Price, Value and Gross Profit (2017-2022)

    • Table AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Product and Service

    • Table Novo Nordisk (Foundation Year, Company Profile and etc.)

    • Table Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Price, Value and Gross Profit (2017-2022)

    • Table Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Product and Service

    • Table Amylin (Foundation Year, Company Profile and etc.)

    • Table Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Price, Value and Gross Profit (2017-2022)

    • Table Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Product and Service


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US